Scarica l'app Stockscreener
13.74
10.84%
-1.67
Dopo l'orario di chiusura:
13.74
Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie
Entry Recap: Why is Enanta Pharmaceuticals Inc stock going upJuly 2025 Opening Moves & Safe Capital Investment Plans - baoquankhu1.vn
Risk Analysis: How sensitive is Enanta Pharmaceuticals Inc to inflationEarnings Miss & AI Optimized Trade Strategies - baoquankhu1.vn
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference - Yahoo Finance
Responsive Playbooks and the ENTA Inflection - Stock Traders Daily
Primary Biliary Cholangitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight - StreetInsider
ENTA SEC FilingsEnanta Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Levels Update: Should I trade or invest in Enanta Pharmaceuticals Inc2025 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
[EFFECT] ENANTA PHARMACEUTICALS INC SEC Filing - Stock Titan
ENTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Can Enanta Pharmaceuticals Inc. reach all time highs this yearNew Guidance & High Accuracy Swing Entry Alerts - mfd.ru
Understanding the Setup: (ENTA) and Scalable Risk - Stock Traders Daily
Is Enanta Pharmaceuticals Inc. (9EP) stock included in top ETFsJuly 2025 Outlook & AI Powered Market Trend Analysis - mfd.ru
Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $20.33 - Defense World
Aug Decliners: Is Enanta Pharmaceuticals Inc backed by strong institutional buyingJuly 2025 Sentiment & Precise Swing Trade Entry Alerts - baoquankhu1.vn
ENTA PE Ratio & Valuation, Is ENTA Overvalued - Intellectia AI
Enanta Pharmaceuticals (ENTA) CSO nets PSU and rTSRU share awards - Stock Titan
Can Enanta Pharmaceuticals Inc. (9EP) stock surprise with quarterly resultsTrade Analysis Summary & Long-Term Growth Portfolio Plans - mfd.ru
What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock - Yahoo Finance
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Equities Analysts Issue Forecasts for ENTA Q2 Earnings - MarketBeat
Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results - simplywall.st
The Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) First-Quarter Results Are Out And Analysts Have Published New Forecasts - 富途牛牛
Enanta (ENTA) Announces $150 Million Mixed Securities Shelf Registration - GuruFocus
Enanta Pharmaceuticals (ENTA) Quarterly Loss Narrows Yet Keeps Profitability Concerns In Investor Focus - Sahm
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for - PharmiWeb.com
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - BioSpace
Enanta Pharma (ENTA): Analyst Reiterates Buy Rating with $20 PT - GuruFocus
HC Wainwright Reaffirms "Buy" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA) - MarketBeat
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 - BioSpace
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 202 - PharmiWeb.com
Enanta Pharmaceuticals (ENTA) Reports Strong Q1 Revenue and Fina - GuruFocus
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot - KVUE
Enanta Pharmaceuticals: Overview of Fiscal First Quarter Earnings - Bitget
Enanta Pharma Earnings Review: Q1 Summary - Benzinga
The Technical Signals Behind (ENTA) That Institutions Follow - Stock Traders Daily
Earnings Preview For Enanta Pharma - Sahm
Primary Biliary Cholangitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Intercept Pharma, Enanta Pharma, COUR Pharma, Novartis, Gannex Pharma, Nanjing Chia-tai Tianqing Pharm - Barchart.com
Enanta Pharmaceuticals (ENTA) Projected to Post Quarterly Earnings on Monday - MarketBeat
Rate Hike: Does Enanta Pharmaceuticals Inc have consistent dividend growthPortfolio Performance Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Insider Sell: What are Asset Entities Incs technical support levelsMarket Trend Report & High Accuracy Trade Alerts - baoquankhu1.vn
Precision Trading with Enanta Pharmaceuticals Inc. (ENTA) Risk Zones - Stock Traders Daily
Enanta (NASDAQ: ENTA) seeks 1.6M-share boost to 2019 equity plan - Stock Titan
CEO Moves: Why is Enanta Pharmaceuticals Inc stock going up2025 Market WrapUp & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Sentiment Review: What are Enanta Pharmaceuticals Inc.’s technical support levelsDividend Hike & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Guidance Update: Why is SWKH stock going downSwing Trade & Verified Short-Term Plans - baoquankhu1.vn
Enanta Pharmaceuticals to Present at the Wells Fargo Securities 2013 Healthcare Conference - AOL.com
Why Enanta Pharmaceuticals Inc. stock appeals to analystsJobs Report & Free Long-Term Investment Growth Plans - bollywoodhelpline.com
Technical Reactions to ENTA Trends in Macro Strategies - Stock Traders Daily
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
JPM26: Enanta outlines strategy to lead in RSV therapeutics - Yahoo Finance
Chipmakers Recap: Is Enanta Pharmaceuticals Inc stock affected by interest rate hikesPortfolio Update Report & Free Technical Pattern Based Buy Signals - Bộ Nội Vụ
Income Plays: What makes Enanta Pharmaceuticals Inc. stock attractive to growth fundsJuly 2025 Market Mood & Growth Focused Entry Point Reports - Bộ Nội Vụ
Downgrade Watch: Why is Enanta Pharmaceuticals Inc stock going upJuly 2025 Summary & Trade Opportunity Analysis - baoquankhu1.vn
Is Enanta Pharmaceuticals Inc. stock trading at a premium valuationJuly 2025 Trade Ideas & Reliable Trade Execution Plans - ulpravda.ru
Will Enanta Pharmaceuticals Inc. stock gain from strong economyAnalyst Downgrade & Safe Swing Trade Setups - Улправда
3.69%
0.68%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):